Pfizer-BioNTech SARS-CoV-2 vaccine effective for wide range of Covid-19–related outcomes

By | March 1, 2021
The Pfizer-BioNTech mRNA vaccine was shown to be 95% effective in preventing severe COVID-19 infection in clinical trials. However, given that the acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues to spread and evolve into several concerning variants, it remained unknown how the vaccine would respond in a real-life setting.